SCHEMBL193665

SCHEMBL193665

CCCC[C@@]1(C(=O)O)CO1

nearest known ligand 0.85

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AKR1B1 P15121 1/20 0.34
PPARG P37231 6/20 0.33
PPARD Q03181 6/20 0.33
PPARA Q07869 6/20 0.33
GPR84 Q9NQS5 5/20 0.33
HDAC11 Q96DB2 5/20 0.33
TSHR P16473 4/20 0.33
ALDH1A1 P00352 2/20 0.33
TLR2 O60603 2/20 0.33
TDP1 Q9NUW8 2/20 0.33
FABP4 P15090 2/20 0.33
PTPN1 P18031 2/20 0.33
SLC22A6 Q4U2R8 1/20 0.33
SLC22A8 Q8TCC7 1/20 0.33
ABCB11 O95342 1/20 0.33
MEN1 O00255 1/20 0.33
ESR1 P03372 1/20 0.33
ALOX15 P16050 1/20 0.33
PDE4A P27815 1/20 0.33
KMT2A Q03164 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6122515 1.00 AKR1B1 (0.34) AKR1B1PPARGPPARDPPARAGPR84
SCHEMBL3029047 1.00 AKR1B1 (0.34) AKR1B1PPARGPPARDPPARAGPR84
SCHEMBL2108728 0.92 GPR84 (0.40) PPARGPPARDPPARAGPR84HDAC11
Palmoxirate SCHEMBL1579204 0.92 GPR84 (0.40) PPARGPPARDPPARAGPR84HDAC11
SCHEMBL2110326 0.92 GPR84 (0.40) PPARGPPARDPPARAGPR84HDAC11
SCHEMBL11464015 0.92 GPR84 (0.40) PPARGPPARDPPARAGPR84HDAC11
SCHEMBL2109685 0.92 GPR84 (0.40) PPARGPPARDPPARAGPR84HDAC11
SCHEMBL2109983 0.92 GPR84 (0.40) PPARGPPARDPPARAGPR84HDAC11
SCHEMBL2108730 0.92 GPR84 (0.40) PPARGPPARDPPARAGPR84HDAC11
SCHEMBL2110319 0.92 GPR84 (0.40) PPARGPPARDPPARAGPR84HDAC11

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1908747-B1 PROCESS FOR PRODUCING OPTICALLY ACTIVE 2-HYDROXYBUTYRIC ESTER KOWA CO (JP) 2012-01-04 EP disclosed
US-7767845-B2 reacting an optically active 2,3-epoxypropionic ester with a methyl Grignard reagent CH3MgX in the presence of a copper catalyst in an amount of 0.05 to 0.5 mol with respect to 1 mol of the 2,3-epoxypropionic ester; for producing pharmaceuticals, pesticides, and industrial products KOWA CO., LTD. (JP) 2010-08-03 US disclosed
US-20090209780-A1 reacting an optically active 2,3-epoxypropionic ester with a methyl Grignard reagent CH3MgX in the presence of a copper catalyst in an amount of 0.05 to 0.5 mol with respect to 1 mol of the 2,3-epoxypropionic ester; for producing pharmaceuticals, pesticides, and industrial products KOWA CO., LTD. (JP) 2009-08-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090209780-A1 reacting an optically active 2,3-epoxypropionic ester with a methyl Grignard reagent CH3MgX in the presence of a copper catalyst in an amount of 0.05 to 0.5 mol with respect to 1 mol of the 2,3-epoxypropionic ester; for producing pharmaceuticals, pesticides, and industrial products CYP4X1, AGL, HACL2 AKR1B1 1203/4885PPARG 1752/4885PPARD 3951/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.